Marker Exploration Corporation
Marker X (銳準生醫) is a biotechnology company specializing in early cancer detection and proteomics analysis services. Leveraging advanced mass spectrometry and proprietary multi-marker algorithms, they offer AI-powered early multi-cancer screening using just 3ml of blood, providing results within 10 working days. Their services aim to detect cancer at its earliest, most treatable stages, significantly improving survival rates. Beyond cancer screening, Marker X plans to expand its diagnostic capabilities to other chronic diseases like cardiovascular conditions and develop companion diagnostics for personalized medication assessment. They collaborate with major teaching hospitals, diagnostic centers, and research institutions, and have been recognized with the 20th National Innovation Award.
Marker Exploration Corporation
Marker X (銳準生醫) is a biotechnology company specializing in early cancer detection and proteomics analysis services. Leveraging advanced mass spectrometry and proprietary multi-marker algorithms, they offer AI-powered early multi-cancer screening using just 3ml of blood, providing results within 10 working days. Their services aim to detect cancer at its earliest, most treatable stages, significantly improving survival rates. Beyond cancer screening, Marker X plans to expand its diagnostic capabilities to other chronic diseases like cardiovascular conditions and develop companion diagnostics for personalized medication assessment. They collaborate with major teaching hospitals, diagnostic centers, and research institutions, and have been recognized with the 20th National Innovation Award.